Showing 6831-6840 of 8885 results for "".
- Recurrence in Patients with Thin Melanomas Linked with Poor Prognosis, Despite Rarityhttps://practicaldermatology.com/news/recurrence-patients-thin-melanomas-linked-poor-prognosis-despite-rarity/2467070/While rare, the recurrence of melanomas in patients with thin melanomas was linked with poorer prognosis and lower survival rates, a single-center analysis reported. "The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm)," the researchers wrote in their study, publi
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- Study: Upadacitinib Produces Sustained Improvements in 140 Weekshttps://practicaldermatology.com/news/study-upadacitinib-produces-sustained-improvements-140-weeks/2467045/Patients with moderate-to-severe atopic dermatitis (AD) experienced sustained improvements in skin signs/symptoms through 140 weeks while receiving upadacitinib and rates of long-term patient-related outcome improvements were numerically higher with upadacitinib 30 mg compared with upadacitinib 1
- Suntegrity Recalls Multiple Lots of Sunscreen Foundationhttps://practicaldermatology.com/news/suntegrity-recalls-multiple-lots-sunscreen-foundation/2467041/Suntegrity Skincare has announced that it is recalling nine lots of Suntegrity Impeccable Skin Sunscreen Foundation (Multiple Shades) due to the discovery of a higher-than-acceptable microbiological mold count (Aspergillus sydowii), according to an FDA alert. According to the man
- More Positive Upadacitinib Data Presentedhttps://practicaldermatology.com/news/more-positive-upadacitinib-data-presented/2467018/New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time
- Sustained Efficacy Following Treatment With Lebrikizumabhttps://practicaldermatology.com/news/sustained-efficacy-following-treatment-lebrikizumab/2467017/A subset of moderate-to-severe atopic dermatitis (AD) patients who were randomly withdrawn from lebrikizumab maintained a stable EASI 90 response up to Week 52 with negligible remaining lebrikizumab serum concentrations, according to research presented at the Revolutionizing Atopic Dermatitis (RA
- FDA Takes Key Step on Tapinarof for ADhttps://practicaldermatology.com/news/fda-takes-key-step-tapinarof-ad/2467002/The US Food and Drug Administration has accepted a supplemental new drug application for Dermavant’s VTAMA (tapinarof) following positive results of a Phase III clinical trial for the drug’s use on atopic dermatitis patients 2 and older, according to GlobalData. Tapinarof, an aryl hydrocar
- FDA Approves First Eyedrops to Treat Mites Living on Eyelasheshttps://practicaldermatology.com/news/fda-approves-first-eyedrops-treat-mites-living-eyelashes/2466993/FDA Approves First Eyedrops to Treat Mites Living on Eyelashes More than 25 million Americans are living with Demodex blepharitis, an underdiagnosed condition that involves mites living on a person’s eyelashes. Demodex blepharitis has gone underdiagnosed for decades because of a l
- Study: Sodium Levels Linked to Atopic Dermatitishttps://practicaldermatology.com/news/study-sodium-levels-linked-atopic-dermatitis/2466978/High sodium levels could be linked to increased risk of developing atopic dermatitis, according to a JAMA Dermatology study published June 5. A cross-sectional study of 215,832 adults found that a 1-g higher estimated 24-hour urine sodium excretion was associated with 11% higher odds of at
- Lebrikizumab Maintains Efficacy Through 52 Weekshttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-through-52-weeks/2466977/New data from a pooled analysis of the ADvocate1 and ADvocate2 trials indicates lebrikizumab was efficacious for treating atopic dermatitis (AD) over a year-long period. “Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient reported ou